Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (“Ribo”), working with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), announce they have reached a first major development milestone in advancing novel siRNA therapies for metabolic dysfunction–associated steatohepatitis (MASH). The companies describe the milestone as part of their ongoing collaboration to develop and progress siRNA-based treatment candidates targeted at the condition.
The announcement is issued from Suzhou, China and Mölndal, Sweden and is attributed to PR Newswire in multiple versions dated July 1 and July 2, 2026, indicating the same event was communicated across outlets. While the provided excerpts do not specify technical trial details such as study phase, patient enrollment, dosing results, or regulatory timing, they consistently frame the update as an early but significant step in the development program for MASH using siRNA therapeutics. The parties present the achievement as progress toward future clinical development activities.
